MindBio Therapeutics’ Post

Another successful meeting discussing the future of Gym-Jam Therapeutics, Inc. It's always exciting meeting with my clients who are experience massive growth! Growing pains are real, but when the right leadership team is at the helm, success is inevitable. #msp #itstrategy #qbr #technologysuccess #strategicplanning

Over the past year, I've had the privilege of attending numerous conferences and networking with investors and executives in the biotech industry. It's evident that securing funding in the current climate has been challenging. However, one consistent theme in my conversations with investors is the crucial importance of a strong and preferably experienced leadership team. Companies cannot just rely on exceptional science; they need the ability to articulate a commercial strategy, a clear vision, and strong operational expertise. This will make them attractive to investors looking for reliable and innovative partners in the high-risk biotech sector. A prime example is Third Arc Bio, which recently raised $165 million to develop oncology and autoimmune biologics. Their success can be attributed not only to their innovative science but also to their exceptional leadership team, led by former Johnson & Johnson executives. This underscores the critical role that experienced leadership plays in gaining investor confidence and driving biotech innovation forward. At GENerX Life, we are actively working with clients worldwide, coaching and advising on the leadership, skills, and competencies required to attract investment. Our expertise ensures that biotech companies are equipped with the right leaders and infrastructure to navigate today's competitive landscape. https://lnkd.in/eTi_TMyJ Visit us to learn more about our services - www.generx.life #Biotech #Leadership #Funding #Innovation #ExecutiveSearch #BiotechFunding #BusinessGrowth #GENerXLife #BiotechLeaders #Agileleaders

I’m excited to share the latest episode of Biotech2050, where I had the pleasure of hosting Jeb Keiper, CEO of Nimbus Therapeutics. In this insightful podcast, we dive deep into Nimbus’ elegant approach to corporate structuring and financing strategy, which has impressively returned over $4B to equity holders. We also discuss the pivotal role of business development in the biotech industry and the art of dealmaking in today’s competitive landscape. Tune in for valuable insights from one of the leading minds in biotech. Link below! #biotech #podcast #drugdevelopment #leadership #clinicaldevelopment #biotechdeals

The latest episode of Biotech2050 is out now, featuring Jeb Keiper, CEO of Nimbus Therapeutics, and hosted by Clora CEO Rahul Chaturvedi. In this episode, Jeb shares his fascinating journey from the labs at MIT and Pfizer to leading Nimbus Therapeutics as CBO and then CEO for nearly a decade. Tune in to gain insights into the unique operating model and financing strategies that have driven Nimbus's success. Jeb also reflects on his many leadership experiences that have shaped him and Nimbus including the importance of taking risks, building a curious team, pioneering a novel deal-making strategy, and fostering a collaborative ecosystem in biotech among CEOs in the last few years - a must-listen for professionals aspiring for executive leadership roles. Check out the new episode using the link below. #biotech #podcast #drugdevelopment #leadership #clinicaldevelopment #biotechdeals

Two weeks to go until our webinar, where Hilary Beck (Eikon Therapeutics), Dean Phillips (Novartis Institute For Biomedical Research) and Susanne Wright (Apollo Therapeutics) will be sharing their advice and experience on running successful drug discovery teams. Have you registered yet? 👉 https://lnkd.in/e8pA3JcW Whether stepping into your first position in a drug discovery team, or an established leader interested in developing and improving your team's strategies, this webinar is for you. #DrugDiscovery #MedicinalChemistry #ScienceCareers #Leadership #Collaboration #Innovation

Antag Therapeutics Announces €80m Series A Financing Led by Versant Ventures https://lnkd.in/eNPGa7ZM Antag Therapeutics Alexander Sparre-Ulrich Versant Ventures Alexander Mayweg Novo Holdings Jeroen Bakker SR One Capital Management Dawn Biopharma Pictet Group More European life science business news at [LSE] Life-Sciences-Europe.com __

Angitia Biopharmaceuticals, a Woodland Hills, CA-based biotech focused on serious musculoskeletal diseases, raised $120M in Series C funding. Bain Capital Life Sciences led the round with participation from Janus Henderson and OrbiMed, 3H Health Investment, Yonghua Capital, Legend Capital, and Elikon Venture. https://lnkd.in/g3Ur-9zm

Did you miss our Q4 Earnings Call? Do you want to hear about our increasing sales, an update on the US sales, the newest commercial agreements, and growth in our Pharma Portfolio? Due to time constraints we did not manage to address all questions we received during the meeting, but you will find it in writing with the recording. Watch the recording and read the Q&A document here: https://loom.ly/ADFKOcg Presenters: Anders Rylander, CEO Anders Morén, CFO Henrik Winther, SVP Business Development Hector Tamburini, Head of US Operations #biovicb #investors #oncology #nasdaqfirstnorth

Calling ALL Drug Hunters - imagine building your next drug discovery program(s) in a company you own and control. #freethefounders Alongside other drug hunters like myself who are there to be your thought partners and help you execute every step of the way. Curie.Bio unlocks an incredible opportunity for founders to build successful therapeutics companies. Founders often suffer from dilution when raising a Series A. Dilution is a product of the capital raised and company valuation. We help founders minimize dilution by maximizing progress with less capital. By reaching critical milestones on blockbuster TPPs, you can raise more capital at a much higher valuation. Last fall, our first portfolio company, Forward Therapeutics, Inc., raised a $50M Series A to generate clinic data! A recent Oppenheimer report revealed this raise was the BIGGEST valuation step up compared to all other therapeutics companies that raised a Series A in the last 12 months. The best part? The founders retained significant ownership in their company. Please don't hesitate to reach out through our website if you have a therapeutic idea worthy of funding. https://lnkd.in/e4NWnqwF 

Biotech Funding is Back: Closing 2024 on a High Note After a challenging stretch in the Life Sciences sector, the biotech market is experiencing a strong revival. Since November, eight companies have successfully completed IPOs, collectively raising over $1.5 billion in just under two months. This resurgence highlights renewed investor confidence, with trailblazing companies like Replimune, Janux Therapeutics, and Revolution Medicines leading the charge and benefiting from their forward-thinking strategies. The recent wave of funding provides a critical boost for organizations with innovative pipelines, equipping them with the resources needed to accelerate commercialization efforts and bring groundbreaking therapies to market. As we close out 2024 on this positive momentum, the biotech industry is well-positioned for an exciting and impactful 2025.